Abound Wealth Management’s Adial Pharmaceuticals ADIL Stock Holding History

Abound Wealth Management’s Portfolio ADIL Stock Details ADIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3	Hold	1	–	–	﹤0.01%	1356
2026 Q1	$2	Hold	1	–	–	﹤0.01%	1487
2025 Q4	$6	Hold	1	–	–	﹤0.01%	1429
2025 Q3	$10	Hold	1	–	–	﹤0.01%	1354
2025 Q2	$9	Hold	1	–	–	﹤0.01%	1296
2025 Q1	$18	Hold	1	–	–	﹤0.01%	1264
2024 Q4	$28	Hold	1	–	–	﹤0.01%	1220
2024 Q3	$27	Hold	1	–	–	﹤0.01%	1296
2024 Q2	$32	Hold	1	–	–	﹤0.01%	1160
2024 Q1	$36	Hold	1	–	–	﹤0.01%	1287
2023 Q4	$51	Hold	1	–	–	﹤0.01%	1305
2023 Q3	$76	Buy	+1	New	+$118	﹤0.01%	1153

Abound Wealth Management's ADIL Position: Q2 2026 in Review

Abound Wealth Management held its Adial Pharmaceuticals (ADIL) position steady in Q2 2026 at 1 share worth $3. The position accounts for ﹤0.01% of the portfolio, ranked #1356.

Abound Wealth Management first reported a position in ADIL in Q3 2023 and has held it in 12 quarters since. The position peaked at $76 in Q3 2023. 1 fund tracked by Wall St. Rank holds ADIL as of Q2 2026.

Abound Wealth Management held 1 share of Adial Pharmaceuticals worth $3 as of Q2 2026.
Abound Wealth Management left its Adial Pharmaceuticals share count unchanged in Q2 2026.
Adial Pharmaceuticals made up ﹤0.01% of Abound Wealth Management's portfolio in Q2 2026, its #1356 holding.
Abound Wealth Management first reported a position in Adial Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
Abound Wealth Management's Adial Pharmaceuticals position peaked at $76 in Q3 2023.
1 fund tracked by Wall St. Rank held Adial Pharmaceuticals as of Q2 2026.

Based on Abound Wealth Management's 13F filing for Q2 2026, filed 10 Jul 2026.